DirtCheapLabs
57 posts

DirtCheapLabs
@DirtCheapLabs
Bloodwork without insurance or markups. Pick the exact tests you want, walk into Quest or Labcorp, flat $10 draw fee. No membership, no junk fees.


@AbudBakri @DrHalMDMBA Very few of us want to go to a clinic and pay $300-$350 per vial for a compounded peptide. 🤷












Earlier this week, Gallup said that 11% of US adults polled were using GLP-1s. There are around 267 million adults in the US. If that 11% number is “real”, that would be roughly 30 million US patients. The problem: in their last quarterly report (Q1 2026), $LLY said the US incretin market was around 2.4 million a week - or roughly 10 million a month - and that includes T2D and pediatric scripts. So is this just a giant sampling issue, or are 20 million patients on compound or RUO? It’s probably a mix of both, but this potentially points to a big issue for pharma. I will note that the same poll indicated that 68% said they were on branded, but it’s possible patients may be shy or not even know the difference. (I’m sure Lilly and Novo are hoping those responses are honest.) That might indicate the real total number of patients on GLP-1s is closer to around 15 million, with just 5 million on compound. 🤷♀️






















